Funding Alert Vol. 24 No. 5 Alert #2 - May 14, 2013

Loading...

Texas Department of State Health Services iconFunding Information Center iconToll free: 1-888-963-7111 ext. 7684 icon(1)Austin phone: (512) 776-7684 icon(1)Fax: (512) 776-7683


The Texas Department of State Health Services Funding Alert is published weekly.  If you wish to subscribe to the Funding Information Center Funding Alert and other services, please call (512) 776-7684 or fill out our online subscription form which can be found at: https://www.dshs.state.tx.us/fic/subscribe.aspx.  Information in the Funding Alert is not copyrighted and may be reproduced. The Texas Department of State Health Services Funding Information Center would appreciate credit for the material used and a copy of the reprint. For information on viewing Adobe Acrobat .pdf and other files, see file viewing information.

Disclaimer: External links to other sites are intended to be informational and do not have the endorsement of the Department of State Health Services. These sites may also not be accessible to persons with disabilities. External e-mail links are provided to you as a courtesy. Please be advised that you are not e-mailing the Texas Department of State Health Services (DSHS) and DSHS policies do not apply should you choose to correspond.


Funding News and Grant Tips

The RFP for EMS Local Projects Grants is out. Please see the listing at http://www.dshs.state.tx.us/fic/AL24-4-4.shtm#A.
From Funding Alert, 4/23/13icon

CDC Urges Second Test to Catch Hepatitis C Infection
Following an eight-site study, the Centers for Disease Control and Prevention (CDC) recommends that all people who test positive for hepatitis C virus (HCV) also should have an HCV RNA test to find out whether they have cleared the virus or they still have it. Approximately 20 percent of HCV-infected people get well without treatment. Since HCV has few symptoms, infected people may not realize they are sick for many years. Untreated HCV, which causes 15,000 deaths each year, can lead to liver damage and liver cancer, the “fastest-growing cause of cancer-related deaths” in the United States.
CDC also recommends that all American baby boomers, people born between the years 1945 to 1965, have an HCV test. CDC Director Thomas Frieden, MD, MPH reported that most of the HCV-infected people identified in the eight-site study (67.2 percent) were baby boomers. This cohort also comprised the majority (72 percent) of HCV-related deaths. Approximately 3 million American adults have HCV, according to CDC, although up to 75 percent of this number do not realize they have the virus.
Frieden advised that new HCV treatments are more effective in curing the infection and preventing transmission of the virus. To view the full report, go to http://www.cdc.gov/mmwr/preview/mmwrhtml/mm62e0507a1.htm.
From CDC HIV/Hepatitis/STD/TB Prevention News Update e-mail, 5/8/13icon


Public Funding Opportunities

AHRQ Patient Centered Outcomes Research (PCOR) Institutional Mentored Career Development Program (K12): RFA-HS-13-008
SOURCE: Agency for Healthcare Research and Quality (AHRQ)
APPLICATION DEADLINE: Letter of Intent: 6/7/13. Application: 7/17/13 by 5 pm local time of applicant organization.
$ AVAILABLE: AHRQ intends to fund approximately eight to 10 awards, for up to a total of $7.5 million.
ELIGIBILITY: Public or nonprofit private institution, such as a university, college, or a faith-based or community-based organization; units of local or state government; eligible agency of the federal government; Indian/Native American tribal government (federally recognized and other than federally recognized); and Indian/Native American tribally designated organization.
PURPOSE: The purpose of this solicitation is to support the career development of post-doctoral and junior research and clinical doctorate faculty scholars in comparative effectiveness research methods, applied to patient-centered outcomes.
CFDA: 93.226
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-HS-13-008.html
From NIH Web site, accessed 5/9/13icon
Subject(s) health professions training, medical research

Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R01): RFA-MH-14-170
SOURCE: National Institute of Mental Health (NIMH), National Institute of Allergy and Infectious Diseases (NIAID), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS)
APPLICATION DEADLINE: Letter of Intent: 8/17/13. Application: 9/17/13 by 5 pm local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
$ AVAILABLE: NIMH intends to commit approximately $1.5 million FY 2014 to fund three to five awards in response to this FOA and the companion R21 FOA. Future year amounts will depend on annual appropriations.
NIAID intends to commit approximately $250,000 in FY 2014 to contribute funding towards awards in response to this FOA.
NIDA intends to commit approximately $2 million in FY2014 to fund four to six awards in response to this FOA and companion R21 FOA.
NINDS intends to commit approximately $1.5 million in FY 2014 to fund three to five awards in response to this FOA and the companion R21 FOA.
ELIGIBILITY: Public/state/private controlled institutions of higher education, nonprofits with and without 501(c)(3) IRS status (other than institutions of higher education), small businesses, for-profit organizations (other than small businesses), state governments, U.S. territories or possessions, Indian/Native American tribal government (federally recognized and other than federally recognized), Indian/Native American tribally designated organizations, non-domestic (non-U.S.) entities, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska native and native Hawaiian serving institutions, regional organizations, eligible agencies of the federal government, and faith-based or community-based organizations.
PURPOSE: This Funding Opportunity Announcement (FOA) invites research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This FOA will support innovative research in five areas: (1) basic research to identify and characterize persistent HIV-1 in CNS derived cells such as macrophages, microglia, and/or astrocytes in the setting of suppressive anti-retroviral therapy, with or without substance use; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of persistent HIV-1 in CNS in relationship to the timing of antiretroviral therapy; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART including effects of chronic substance use; (4) assessment of current and emerging eradication approaches on whether and/or how well they have successfully reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes; and (5) assessment of CNS toxicity and adverse impact of current and emerging eradication strategies. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.
CFDA: 93.242, 93.853, 93.856, 93.855, 93.279
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-14-170.html
From NIH Web site, accessed 5/9/13icon
Subject(s) HIV/AIDS research, substance abuse research

Eradication of HIV-1 from CNS Reservoirs: Implications for Therapeutics (R21): RFA-MH-14-171
SOURCE: National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Institute of Neurological Disorders and Stroke (NINDS)
APPLICATION DEADLINE: Letter of Intent: 8/17/13. Application: 9/17/13 by 5 pm local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
$ AVAILABLE: NIMH intends to commit approximately $1.5 million FY 2014 to fund three to five awards in response to this FOA and the companion R21 FOA. Future year amounts will depend on annual appropriations.
NIDA intends to commit approximately $2 million in FY2014 to fund four to six awards in response to this FOA and companion R21 FOA.
NINDS intends to commit approximately $1.5 million in FY 2014 to fund three to five awards in response to this FOA and the companion R21 FOA.
ELIGIBILITY: Public/state/private controlled institutions of higher education, nonprofits with and without 501(c)(3) IRS status (other than institutions of higher education), small businesses, for-profit organizations (other than small businesses), state governments, U.S. territories or possessions, Indian/Native American tribal government (federally recognized and other than federally recognized), Indian/Native American tribally designated organizations, non-domestic (non-U.S.) entities, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska native and native Hawaiian serving institutions, regional organizations, eligible agencies of the federal government, and faith-based or community-based organizations.
PURPOSE: This Funding Opportunity Announcement (FOA) invites research grant applications to address the problem of HIV-1 persistence focused solely on the central nervous system (CNS) of HIV-infected persons treated with Highly Active Anti-Retroviral Therapy (HAART). This FOA will support innovative research in five areas: (1) basic research to identify and characterize persistent HIV-1 in CNS derived cells such as macrophages, microglia, and/or astrocytes in the setting of suppressive anti-retroviral therapy, with or without substance use; (2) basic research to determine the mechanisms involved in the temporal establishment, maintenance, and resurgence of persistent HIV-1 in CNS in relationship to the timing of antiretroviral therapy; (3) development of physiologically relevant animal models and CNS-based cellular assays that recapitulate HIV-1 persistence and latency in the presence of effective HAART including effects of chronic substance use; (4) assessment of current and emerging eradication approaches on whether and/or how well they have successfully reactivated persistent HIV from CNS-derived cells such as macrophages, microglia and astrocytes; and (5) assessment of CNS toxicity and adverse impact of current and emerging eradication strategies. Applications ranging from basic to translational research in domestic and international settings are of interest. Multidisciplinary research teams are encouraged but not required.
CFDA: 993.242, 93.853, 93.856, 93.279
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-14-171.html
From NIH Web site, accessed 5/9/13icon
Subject(s) HIV/AIDS research, substance abuse research

Indo-U.S. Vaccine Action Program (VAP) Small Research Grant Program (R03): PA-13-179
SOURCE: National Institute of Allergy and Infectious Diseases (NIAID)
APPLICATION DEADLINE: 2/16, 6/16, 10/16. Expires 5/8/16.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: Public/state/private controlled institutions of higher education, nonprofits with and without 501(c)(3) IRS status (other than institutions of higher education), small businesses, for-profit organizations (other than small businesses), state governments, U.S. territories or possessions, Indian/Native American tribal government (federally recognized and other than federally recognized), Indian/Native American tribally designated organizations, non-domestic (non-U.S.) entities, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska native and native Hawaiian serving institutions, regional organizations, eligible agencies of the federal government, and faith-based or community-based organizations.
PURPOSE: Scientific cooperation between India and the U.S. has taken place under a variety of bilateral umbrella agreements, including the Indo-U.S. Science and Technology (S&T) Sub-Commission, the Gandhi-Reagan S&T Initiative, the U.S.-India Fund, and the current S&T Cooperation Agreement. Building upon these agreements and initiatives, representatives of the United States and the Government of India signed a Memorandum of Understanding on July 9, 1987 implementing the Indo-U.S. Vaccine Action Program (VAP) in order to expand collaborative vaccine research. The goal of the VAP is to support collaborative vaccine-related research projects that ultimately reduce the burden of infectious diseases of importance in India, the U.S., the South Asian region and globally. Applications are encouraged from organizations/institutions that propose to conduct vaccine-related research through U.S.-Indo collaborations on the following: dengue, influenza (including avian influenza), malaria, enteric diseases, HIV/AIDS, and tuberculosis. Basic, translational, clinical, or epidemiological vaccine research may be proposed.
CFDA: 93.855; 93.856
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/pa-files/PA-13-179.html
From NIH Web site, accessed 5/9/13icon
Subject(s) medical research, HIV/AIDS research

Structural Interventions, Alcohol Use, and Risk of HIV/AIDS (R01): PA-13-191
SOURCE: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
APPLICATION DEADLINE: 2/5, 6/5, 10/5. Expires 5/8/16.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: Public/state/private controlled institutions of higher education, nonprofits with and without 501(c)(3) IRS status (other than institutions of higher education), small businesses, for-profit organizations (other than small businesses), state governments, U.S. territories or possessions, Indian/Native American tribal government (federally recognized and other than federally recognized), Indian/Native American tribally designated organizations, non-domestic (non-U.S.) entities, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska native and native Hawaiian serving institutions, regional organizations, eligible agencies of the federal government, and faith-based or community-based organizations.
PURPOSE: This FOA encourages R01 research grant applications from institutions/organizations that propose to investigate the effectiveness of structural interventions aimed at reducing the risk of HIV/AIDS transmission by changing the environment of alcohol use. Although a variety of structural and environmental interventions have been employed successfully to reduce other drinking-related problems, similar research extending into the realm of HIV/AIDS risk reduction is still in its developing stages.
CFDA: 93.273
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/pa-files/PA-13-191.html
From NIH Web site, accessed 5/9/13icon
Subject(s) HIV/AIDS research, HIV/AIDS education/prevention, substance abuse research

Structural Interventions, Alcohol Use, and Risk of HIV/AIDS (R21): PA-13-192

SOURCE: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
APPLICATION DEADLINE: 2/16, 6/16, 10/16. Expires 5/8/16.
$ AVAILABLE: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
ELIGIBILITY: Public/state/private controlled institutions of higher education, nonprofits with and without 501(c)(3) IRS status (other than institutions of higher education), small businesses, for-profit organizations (other than small businesses), state governments, U.S. territories or possessions, Indian/Native American tribal government (federally recognized and other than federally recognized), Indian/Native American tribally designated organizations, non-domestic (non-U.S.) entities, Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), Alaska native and native Hawaiian serving institutions, regional organizations, eligible agencies of the federal government, and faith-based or community-based organizations.
PURPOSE: This FOA encourages R21 research grant applications from institutions/organizations that propose to investigate the effectiveness of structural interventions aimed at reducing the risk of HIV/AIDS transmission by changing the environment of alcohol use. Although a variety of structural and environmental interventions have been employed successfully to reduce other drinking-related problems, similar research extending into the realm of HIV/AIDS risk reduction is still in its developing stages.
This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope that encourages applications under the R01 grant mechanism.
CFDA: 93.273
CONTACT: Please see URL for multiple contacts. For more information see http://grants.nih.gov/grants/guide/pa-files/PA-13-192.html
From NIH Web site, accessed 5/9/13icon
Subject(s) HIV/AIDS research, HIV/AIDS education/prevention, substance abuse research

Tobacco Prevention and Control Coalitions: SA/TPCC-0564.1
SOURCE: Texas Department of State Health Services (DSHS), Mental Health and Substance Abuse Division
APPLICATION DEADLINE: Letter of Intent: 5/29/13. Applications: 6/3/13 at 2 pm CST.
$ AVAILABLE: In Fiscal Year 2014, approximately $1,750,000 is expected to be available to fund four to six contracts.
ELIGIBILITY: City and county health departments, hospital districts, community-based organizations, and/or tribal governments.
PURPOSE: The Department of State Health Services (DSHS or the Department) Mental Health and Substance Abuse Division (MHSA), Tobacco Prevention and Control Program announces the expected availability of fiscal year (FY) 2014 tobacco funds to provide city and county health departments, hospital districts, community-based organizations, and/or tribal governments with funds to manage a comprehensive community Tobacco Prevention and Control Coalition (TPCC). DSHS intends to fund comprehensive coalition services in cities or counties with a population of 500,000 or less. Cities or counties with more than 500,000 population can only be awarded coalition funding for identified zip codes comprised of a target population with less than 500,000 to provide comprehensive services for persons experiencing documented tobacco-related health disparities.
CFDA: none
CONTACT: Linda Rodriguez, (512) 776-7470, e-mail: SA-RFP@dshs.texas.gov. For more information see http://esbd.cpa.state.tx.us/bid_show.cfm?bidid=105663
From Electronic State Business Daily Web site, accessed 5/8/13icon.
Subject(s) smoking/tobacco, substance abuse education/prevention


Private Funding Opportunities

Children's Leukemia Research Association Invites Applications for Research Projects
SOURCE: Children's Leukemia Research Association
APPLICATION DEADLINE: 6/30/13.
$ AVAILABLE: Grants of up to $30,000 will be awarded.
ELIGIBILITY: Any doctor at the Ph.D. or M.D. level who is involved in research focused on finding the causes of and a cure for leukemia may apply.
PURPOSE: The Children's Leukemia Research Association is accepting applications from investigators for promising research into childhood leukemia.
Grants will be awarded for the most promising projects, with the goal of isolating the causes of and finding a cure for childhood leukemia. Funding from other sources is permissible but CLRA funding objectives should not duplicate those of other funding sources.
CONTACT: Please see URL for contact information. For more information see http://www.childrensleukemia.org/researchgrants.html
From Philanthropy News Digest e-mail, 5/3/13icon
Subject(s) children's health, cancer research, health professions training

Clinical Research Training Fellowship in Ataxia
SOURCE: American Brain Foundation
APPLICATION DEADLINE: 10/1/13.
$ AVAILABLE: Fellowships of $55,000 per year for two years.
ELIGIBILITY: To be eligible, applicants must be an AAN member who has completed a residency, a fellowship, or a postdoctoral fellowship (for a Ph.D.) within the past five years. Priority will be given to those early in their clinical research careers.
PURPOSE: Fellowships will be awarded to early-career investigators interested in an academic career in clinical research. An additional $10,000 per year will be awarded for tuition to support formal education in clinical research methodology at the applicant's institution or elsewhere. Supplementation of the stipend with other grants or by the fellowship institution is permissible, but fellows may not accept other fellowships, similar awards, or have another source of support for more than 50 percent of their research salary during the first year of the fellowship.
CONTACT: Kristin Roehl, (612) 928-6082, e-mail: kroehl@aan.com. For more information see http://www.ataxia.org/pdf/Clinical_Research_Training_Fellowship_in_Ataxia.pdf
From Philanthropy News Digest e-mail, 5/3/13icon
Subject(s) medical research, health professions training

Frances Fowler Wallace Award to Fund Original Mental Health Research
SOURCE: The Hogg Foundation for Mental Health
APPLICATION DEADLINE: Unlike most of our grant initiatives, scholarships and fellowships, applications for the Wallace Award are reviewed on a rolling basis and may be submitted at any time.
$ AVAILABLE: The award provides up to $1,500 for research-related expenses.
ELIGIBILITY: Doctoral students at The University of Texas at Austin are eligible to apply for the Wallace award.
PURPOSE: The Hogg Foundation is supportive of quality research that deepens our understanding of both the causes of mental illness and intervention models and approaches that promote mental health, wellness and recovery. The Frances Fowler Wallace Memorial for Mental Health Dissertation Award, established in 1974 to partially fund doctoral dissertation research on “the cause, treatment, cure, and prevention of mental disease, mental illness, and mental disorders,” is one example of the foundation’s commitment to utilizing its grantmaking capacity to promote rigorous, quality research in mental health.
CONTACT: For more information go tohttp://www.hogg.utexas.edu/
From The Hogg Blogg e-mail, 5/8/13icon
Subject(s) mental health, health professions training

New Alzheimer's Drug Trials
SOURCE: Alzheimer's Drug Discovery Foundation
APPLICATION DEADLINE: 6/5/13, 9/5/13, and 12/5/13. Letters of Intent are required at least two weeks prior to the application deadline.
$ AVAILABLE: The foundation will award grants of up to $1 million.
ELIGIBILITY: Nonprofit academic institutions and for-profit biotechnology companies are eligible to apply.
PURPOSE: The Alzheimer's Drug Discovery Foundation is accepting proposals to support clinical trials of innovative drugs for the treatment of Alzheimer's disease.
Through its Program to Accelerate Clinical Trials, the foundation will award grants for biomarker-based pilot trials of Alzheimer's drugs at the proof-of-concept phase.
CONTACT: Please see URL for contact information. For more information see http://www.alzdiscovery.org/
From Philanthropy News Digest e-mail, 5/3/13icon
Subject(s) mental health, health professions training, medical research

Proposals for 2013 Research Funding
SOURCE: Mesothelioma Applied Research Foundation
APPLICATION DEADLINE: 8/2/13.
$ AVAILABLE: Grants of up $50,000 for up to two years will be awarded to qualified investigators.
ELIGIBILITY: Early-stage investigators with appropriate experience and training or established investigators with a record of accomplishments that have advanced their field are eligible to apply.
PURPOSE: The Mesothelioma Applied Research Foundation is accepting applications for its 2013 mesothelioma research funding cycle.
Grants will be awarded to qualified investigators for projects related to bench work, translational, or clinical research that is not presently funded or is pending review and may be conducted through a nonprofit academic, medical, or research institution. Qualified researchers will also receive facilitated access to the National Mesothelioma Virtual Bank, expedited review of requests to use the NMVB, and direct no-cost access to materials in the bank, as well as enhanced collections from the main sites.
Projects of special interest include, but are not limited to, investigations of strategies for early detection of new or progressive disease, definition of targetable differences between normal and transformed mesothelium, and development of novel strategies for treatment, therapeutic intervention, and determination of clinical/molecular determinants for prognosis.
CONTACT: Please see URL for contact information. For more information see http://www.curemeso.org/site/c.kkLUJ7MPKtH/b.4097447/k.2CDD/Grants_for_Mesothelioma_Research.htm
From Philanthropy News Digest e-mail, 5/3/13icon
Subject(s) cancer research

Proposals for Blood Cancer Research Projects
SOURCE: Leukemia & Lymphoma Society
APPLICATION DEADLINE: Letter of Intent: 6/3/13.
$ AVAILABLE: Through the Quest for Cures initiative, LLS, in partnership with biopharmaceutical company Celgene, will award two-year grants of between $200,000 and $400,000 a year for research projects that have a measurable impact over the next five to ten years on the diagnosis or treatment of patients with hematologic malignancies. Additional funding may be available for projects that have demonstrated exceptional progress in the initial two years.
ELIGIBILITY: Applicants must hold an M.D., Ph.D., or equivalent degree, and work for a domestic or foreign nonprofit organization, such as a university, a college, a hospital, or an academic laboratory. Applications may involve multiple institutions, but the applicant should have an independent research or academic position and his/her academic institution will be responsible for signing off on all terms of the grant agreement.
PURPOSE: The Leukemia & Lymphoma Society is accepting Letters of Intent from researchers for projects to identify and develop safer, more effective treatments for patients with blood cancers.
Specifically, the initiative will award grants in the following priority areas:
* Tumor cell clonal heterogeneity: This grant will support researchers seeking novel approaches for measuring and monitoring clonal heterogeneity and assessing its contribution to the response or resistance to therapy.
* New molecular stratification mechanisms: Recipients of this grant will work to identify key subsets of patients with B-cell malignancies to help predict which patients will have poor outcomes from current standard therapies so they may be directed to alternative therapies.
* Bone marrow and lymph node microenvironments: Researchers will seek to enhance the understanding of the role that the bone marrow and lymph node microenvironments play in either responding to or resisting therapy.
CONTACT: For additional questions regarding LLS research programs, eligibility and application processes, please contact Sammy Hattar, Director of Research Administration: Sammy.Hattar@lls.org or (914) 821-8290. For more information see http://www.lls.org/#/researchershealthcareprofessionals/academicgrants/quest_for_cures/
From Philanthropy News Digest e-mail, 5/8/13icon
Subject(s) cancer research


Events

Grant Writing Certificate Program
SPONSOR: Center for Community Based & Nonprofit Organizations at Austin Community College (CCBNO ACC)
WHEN: June 10-14, 9 am to 4 pm.
WHERE: Austin Community College-Highland Business Center, 5930 Middle Fiskville Road, Room TBD, (Austin, TX).
DESCRIPTION: The Grant Writing Certificate Program provides an intensive opportunity to acquire the knowledge and practice the skills necessary to succeed in today's competitive grant writing environment. Instructor Jack Smith is an accomplished grant writer with an easygoing style who packs each day with a vast amount of content and expertise.
COST: $450 TANO members / $650 non-TANO members.
CONTACT: Lisa Dent, (512) 223-7051, e-mail: lisa.dent@austincc.edu.
From Center for Community Based & Nonprofit Organizations at Austin Community College Web site, accessed 5/10/13icon

Effective Communication
SPONSOR: Center for Community Based & Nonprofit Organizations at Austin Community College (CCBNO ACC)
WHEN: July 12, 9 to 11 am.
WHERE: Austin Community College-Highland Business Center, 5930 Middle Fiskville Road, Room TBD, (Austin, TX).
DESCRIPTION: Understanding how your personal communication styles work for or against you will improve your ability to have meaningful interactions with others, and will positively influence how they perceive you, which will ultimately improve your relationships with co-workers, volunteers, board members and even your boss.
COST: $20.
CONTACT: Lisa Dent, (512) 223-7051, e-mail: lisa.dent@austincc.edu.
From Center for Community Based & Nonprofit Organizations at Austin Community College Web site, accessed 5/10/13icon


icongreen Return to Alert

 

 

  • Loading...
Last updated January 08, 2014